Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.48 |
| ▸ | TNF | P01375 | 3/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | LYN | P07948 | 2/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.41 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.40 |
| ▸ | CIT | O14578 | 1/20 | 0.40 |
| ▸ | MUSK | O15146 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248487 | 0.91 | MAPK14 (0.49) | THRBMAPK14TNFBRAFABL1 | |
| SCHEMBL4092545 | 0.90 | MAPK14 (0.61) | THRBMAPK14TNFBRAFABL1 | |
| SCHEMBL4095891 | 0.85 | MAPK14 (0.51) | MAPK14TNFBRAFABL1EGFR | |
| SCHEMBL6249247 | 0.83 | MAPK14 (0.49) | THRBMAPK14TNFBRAFABL1 | |
| SCHEMBL5388339 | 0.81 | MAPK14 (0.53) | THRBMAPK14TNFBRAFRAF1 | |
| SCHEMBL6249256 | 0.80 | MAPT (0.48) | THRBMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5384351 | 0.80 | MAPK14 (0.51) | THRBMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4092120 | 0.78 | MAPK14 (0.71) | MAPK14TNFBRAFABL1EGFR | |
| SCHEMBL4096572 | 0.78 | MAPK14 (0.57) | MAPK14TNFBRAFABL1EGFR | |
| SCHEMBL6913451 | 0.77 | MAPK14 (0.51) | MAPK14TNFBRAFABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | MOSS NEIL | 2007-07-05 | — | — | US | claimed |
| US-7211575-B2 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | claimed |
| EP-1427412-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-06-16 | — | — | EP | claimed |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| US-7276491-B2 | Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | MOSS NEIL | 2007-07-05 | — | — | US | disclosed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1784224-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2007-05-16 | — | — | EP | disclosed |
| US-20070099832-A1 | Combination Therapy with p38 MAP Kinase Inhibitors and their Pharmaceutical Compositions | SIMIANER STEFAN | 2007-05-03 | — | — | US | disclosed |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-06-27 | — | — | US | disclosed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | TNF, IL2, IL1B | THRB 1384/4885MAPK14 922/4885TNF 1/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | THRB 861/4885MAPK14 74/4885TNF 745/4885 |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | THRB 4202/4885MAPK14 2740/4885TNF 2/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | THRB 2434/4885MAPK14 44/4885TNF 707/4885 |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | TNF, IL2, IL1B | THRB 1384/4885MAPK14 922/4885TNF 1/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | THRB 4202/4885MAPK14 2740/4885TNF 2/4885 |
| US-20070099832-A1 | Combination Therapy with p38 MAP Kinase Inhibitors and their Pharmaceutical Compositions | MAPKAPK2, MAP3K1, MAP3K2 | THRB 1436/4885MAPK14 39/4885TNF 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.